Does Aspirin Reduce Vascepa's Benefits?
Vascepa (icosapent ethyl) lowers cardiovascular risk in high-risk patients, but daily aspirin use cuts its efficacy by about 28% based on the REDUCE-IT trial. In the trial's 8,179 patients with elevated triglycerides and cardiovascular disease or risk factors, those on 81 mg aspirin daily saw a 24% relative risk reduction in major adverse cardiovascular events (MACE: CV death, nonfatal MI, nonfatal stroke, urgent coronary revascularization) versus placebo. Without aspirin, the reduction was 52%.[1][2]
Why the Interaction Happens
Aspirin, an antiplatelet, may blunt Vascepa's triglyceride-lowering and anti-inflammatory effects on plaques. REDUCE-IT subgroup analysis showed consistent trends across doses, but higher aspirin use correlated with weaker outcomes. This held after adjusting for factors like age, diabetes, and statin use.[1]
Clinical Trial Breakdown
- Full Cohort (n=8,179): Vascepa reduced MACE by 25% overall.
- Aspirin Users (n=62%): 24% reduction.
- No Aspirin (n=38%): 52% reduction.
No difference in bleeding risk between groups.[1][2]
| Group | MACE Risk Reduction |
|-------|---------------------|
| All patients | 25% |
| On aspirin | 24% |
| No aspirin | 52% |
Should Patients Stop Aspirin?
Guidelines still recommend low-dose aspirin (75-100 mg) for secondary prevention in eligible patients, as its benefits often outweigh this interaction. Discuss with a doctor—stopping aspirin raises clotting risk. REDUCE-IT authors noted the absolute risk reduction remained positive even with aspirin.[1][3]
Other Drug Interactions with Vascepa
Vascepa has few major interactions beyond antiplatelets like aspirin or clopidogrel (similar 20-30% efficacy drop). Statins enhance benefits; avoid fibrates due to myopathy risk.[4]
[1]: Yonker et al., REDUCE-IT Subgroup Analysis, J Am Coll Cardiol 2021
[2]: Bhatt et al., REDUCE-IT Primary Results, NEJM 2019
[3]: AHA/ACC Guidelines on Aspirin
[4]: Vascepa Prescribing Information